Evonik's Earnings Beat the Top Line but Not the Consensus, as BASF Waits in the Wings
Published on 11/03/2026 at 16:01 | Editorial boerse-global.de
Evonik's third-quarter figures land with a split verdict. The specialty chemicals maker posted a 40% jump in adjusted EBITDA to €629 million for the 2026 third quarter, yet the number still fell just shy of the €633.2 million analysts had penciled in. Growth, in other words, is not the same thing as a positive surprise — and investors would do well to keep the two apart.
Revenue climbed 13% to €3.825 billion, a touch above the €3.83 billion figure circulating in some summaries. Management credits both higher selling prices and larger volumes, which means the earnings advance rests on more than a pure pricing effect. There is a tailwind from elsewhere too: Reuters reports supply disruptions among Asian competitors stemming from the Middle East crisis, a development that flatters Evonik's competitive position. Whether that support proves durable is another question entirely — a softer field of rivals is not the same as genuinely stronger demand.
Two Yardsticks, Two Pictures
The gap between the headline operating metric and the bottom line deserves close attention. Adjusted EBITDA shows a clear step up. Net income does not. Evonik remained in the red for the quarter, with a consolidated loss of €53 million, an improvement on the prior-year quarter's €106 million shortfall. The company also booked €313 million in provisions for additional ETM measures. A narrower loss is not a return to profit, and anyone assessing the recovery should resist equating the adjusted figure with earnings after every charge.
Should investors sell immediately? Or is it worth buying Evonik?
On the outlook, Evonik expects full-year 2026 adjusted EBITDA in the upper half of its €2.0 billion to €2.2 billion range. The band itself is unchanged; the company has simply shifted the expected center of gravity upward. It also anticipates fourth-quarter earnings above the prior-year level. Both remain forecasts, not banked results.
A Conversation, Not a Deal
The stronger operating story gives Evonik a firmer footing from which to justify its standalone course. On Friday the executive board declined to enter negotiations with BASF over a voluntary public takeover offer, while explicitly leaving the door open to a purely informational and confidential exchange. That distinction matters: willingness to talk is neither approval of a transaction nor the start of takeover talks.
Roughly a week earlier, Reuters reported that BASF had raised its offer to €24 per share. BASF chief executive Markus Kamieth stressed at the same time that he does not intend to overpay, and that any deal would have to create value for BASF shareholders. Two different yardsticks thus sit side by side — Evonik's improving operations support a valuation on its own merits, while BASF ties any acquisition to value creation for its own investor base.
Shares gained 2.0% on the day. For Evonik holders, the decisive line runs between a brightening business outlook and a transaction that remains unresolved. The stronger numbers furnish concrete arguments for the former. They do nothing yet to settle the latter.
Ad
Evonik Stock: New Analysis - 3 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
